MSD Greece’s Post

At Astellas, we recognise that how we show up to work and behave is intrinsically linked to our ambition to turn innovative science into value for patients. The first of five principles helping us amplify our impact for the benefit of patients is ‘outcome focus over task orientation’. It is all too easy to lose yourself in your daily ‘to-do’ list at the expense of achieving the goals that really matter. Listen to the clip to find out why, with stakes this high, we are actively guarding against it, ready to course correct at a moment’s notice.

Did you know that real-world-evidence is a key component to understand how new innovations and technologies can be embedded to allow benefit for patient and the healthcare system? 📊Driving this type of research with access to high quality health datasources is crucial 🇫🇷That was one of many topics adressed during a two-day meeting at Novartis France in Paris 🙏Thanks Marion Pinet, Guillaume Wendt, PhD and Evgeniya Novoderezhkina, PhD for good collaboration in the planning and during the gathering 🌍A big thank you to the global team for joining and providing perspective- Adrian Cassidy, Elena Panitti, Luis Prieto 🤝Strong collaboration across countries in Europe is key to drive this area of interest further forward - combining key needs with world leading data-infrastructures we have in our countries🇬🇧🇩🇪🇫🇷🇳🇴🇸🇪🇫🇮🇩🇰 The Nordic team looks forward to future touchbases - Maija Wolf, Teresa Hallerbäck ,Björn Paulsson, Øyvind Fensgard, Jayson Swanson Habib Karam, Tobias Bäckström,Johan Kahlström, Jacob Brun ,Gerrit Zijlstra, Patrick Meshaka, Andre Schmidt Novartis Norge, Tony Terzis, Veronika Barrabes

#AMR is an important issue - if you want an update on progress being made on addressing the ‘AMR silent pandemic’ do register for this free webinar. Looking forward to chairing the webinar, insightful updates from the expert panel and an engaging Q&A.

🌍✨ Day 2: The Power of Public-Private Partnerships in Controlling AMR ✨🌍 Today, we shine a spotlight on the collaboration between industry and the public sector in our efforts to mitigate AMR. Public-private partnerships are essential for driving innovation, advancing research, and implementing effective solutions to curb AMR. 🌐🤝 "Developing innovative antibacterial products and making them accessible worldwide are complex objectives that require all hands on deck. From our experience at CARB-X, it is crystal-clear that leveraging the combined resources and expertise of governments, industry, academia and civil society is the only way to stay ahead in the fight against drug-resistant bacteria. This is why public-private partnerships are so crucial if we want to stop superbugs." Damiano de Felice, Chief of External Affairs, CARB-X These partnerships are paving the way for new antimicrobial products, better diagnostic tools, and innovative strategies. By combining the strengths of private companies and public organisations, we can leverage resources and expertise to create sustainable solutions. We encourage industry stakeholders to actively engage in the fight against AMR by: 🔹 Investing in R&D - Support the development of new antimicrobial agents and alternatives. 🔹 Collaborating - Partner with public entities and other organisations to share knowledge and resources. Let’s harness the power of public-private partnerships to create a healthier future for all! 🌍💪 Stay tuned for more insights as we continue our journey through #WAAW2024! #OneHealth #EducateAdvocateAct #GlobalCollaboration #AMR Video credit: WHO

On the intersection of healthcare and creativity.

🚀I'm thrilled to announce that I'll be speaking at the upcoming DIA Global Meeting, taking place in San Diego, US, between 16-20 June, on a topic that's close to my heart: Digital Biomarkers as Clinical Endpoints - The Road to Regulatory Acceptability. 💡In an era where technology and healthcare are increasingly intertwined, digital biomarkers offer groundbreaking potential to revolutionize clinical trials and patient care. This session will explore how we can harness these innovative tools to meet regulatory standards and improve health outcomes worldwide. 🔍In my speech, I'll be diving deep into the current landscape of digital biomarkers, with the focus on Europe, and exploring the path towards wider regulatory acceptance. I'll be sharing real-world examples and @Bayer’s perspective to help us navigate this exciting new frontier in clinical research. 🙏I'm especially grateful to Susan Awad and Lina AlJuburi for inviting me to share the industry insights on this critical topic. Digital biomarkers have the potential to revolutionize clinical trials, offering a more objective and efficient way to measure treatment effects. However, their regulatory acceptance is still evolving. 🌐 If you're interested in the future of clinical trials and the potential of digital biomarkers, then be sure to join the conference! I look forward to a stimulating discussion and the opportunity to connect with fellow leaders in the healthcare industry. hashtag #digitalhealth hashtag #clinicaltrials hashtag #regulatoryaffairs hashtag #globalhealthcare hashtag #digitalbiomarkers hashtag #DIA2024 https://ow.ly/XxFR50QwsWt Steve Berman – BIO, Deputy Vice President, Science and Regulatory Affairs Strategy Gul Erdemli – Novartis, Global Program Regulatory director Anindita (Annie) Saha – FDA Associate Director for Strategic Initiatives, Digital Health Center of Excellence Marwan Fathallah, President and Chief Executive Officer, DIA Global Ania Mitan, DIA Susan Benedetti, MSOL, DES, Senior Project Manager, Global Annual Meeting Maureen Lamplugh, Retired, Former Annual Meeting Program Manager, DIA Christian Rommel, Bayer AG Stefan Oelrich, Bayer AG Elena Popa, Bayer AG Antoine Manson, Bayer AG

For executives at rare disease drug developers, there remains uncertainty on how to best manage IRA risk in the context of product strategy. The IRA forces us to reconsider the traditional new product planning playbooks and instead incorporate a more nuanced assessment of IRA risk into decision making regarding indication prioritization, clinical development strategy, and forecasting. In our latest blog, we offer a framework to incorporate IRA risk into new product planning with our colleagues at Parexel. Read here: https://bit.ly/3xUFpXo Olivia (Dickey) Foroughi, MPH, Douglas Mullen, Brian M. Duda, Carrie Jones #raredisease #orphandrug #newproductplanning #NPP

“We’re able to give people with debilitating disease their lives back…if you’re part of that kind of enterprise, you can get up every day knowing you’re moving the needle for society.” Check out our CEO Vas Narasimhan talk about what makes our work at Novartis—and the way we work together—so meaningful on the latest episode of The David Rubenstein Show, Peer-to-Peer Conversations: #Unbossed #NovartisTogether

“We’re able to give people with debilitating disease their lives back…if you’re part of that kind of enterprise, you can get up every day knowing you’re moving the needle for society.” Check out our CEO Vas Narasimhan talk about what makes our work at Novartis—and the way we work together—so meaningful on the latest episode of The David Rubenstein Show, Peer-to-Peer Conversations: #Unbossed #NovartisTogether